WilmerHale blends transactional, regulatory and litigation expertise to serve clients from various industries such as biotech, pharma, diagnostics and medical devices, as well as financial institutions, and leading academic institutions. The firm advises companies navigating complex scientific innovation and regulatory scrutiny, including emerging technologies such as gene therapies, biologics, and AI-driven discovery, development and diagnostic products. Judith Hasko serves as co-chair of the life sciences practice from Palo Alto, focusing on the structuring and negotiation of strategic, intellectual property and tech-based commercial transactions. Alongside her, co-chair Stuart Falber in Boston serves as counsel for a broad range of life sciences clients, including newly public and mature public companies.
Legal 500 Editorial commentary
Key clients
- Sonoma Biotherapeutics
- Exelixis
- Bridgebio
- Character Biosciences
- Curis, Inc.
- Roche
- Molecular
- CytomX
- Shape Therapeutics
- Pliant Therapeutics
- Terns Pharmaceuticals
Work highlights
Advising longtime client Thermo Fisher Scientific.
Represented Ratio Therapeutics Inc, a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, in its exclusive worldwide license and collaboration agreement for the development of a Somatostatin Receptor 2 (SSTR2) radiotherapeutic candidate for cancer.
Represented Roche in its exclusive collaboration and licensing agreement with Zealand Pharma.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Practice head
Stuart Falber; Judith Hasko
Other key lawyers
Steve Barrett; Cynthia Mazareas